DCA Vantage Analyzer

Drive diabetic patient compliance with trusted, clinically proven results

DCA Vantage Analyzer
 
Contact Us
DCA Vantage Analyzer
DCA Vantage Analyzer
DCA Vantage Analyzer
Actionable results in 7 minutes or less

Minimize the need for follow-up visits with a full spectrum of results: HbA1c (NGSP certified and IFCC certified/CLIA waived), Estimated Average Glucose*, Albumin, Creatinine, and Albumin-to-Creatinine Ratio results.
*Not available in the US

DCA buy, buy vantage analyzer
Click above to order

Click on the ‘Features & Benefits’ tab above to find out more about our products and how to buy.

DCA Vantage Analyzer
Easy to use in the office or clinic

No sample or reagent preparation is required, and the system provides versatile data management and reporting options

Robust technology delivers proven performance
Robust technology delivers proven performance

The analyzer leverages robust technology and delivers the proven performance of the DCA HbA1c and DCA Microalbumin/Creatinine tests highlighted in more than 140 clinical articles.

Manage diabetes testing in decentralized settings
Manage diabetes testing in decentralized settings

Powerful functionality enables POC coordinators to better manage diabetes testing in decentralized settings. When supported by Siemens RAPIDComm® Data Management System, coordinators can oversee and troubleshoot multiple connected analyzers in real time.

Provide the clinical confidence your patients deserve. The DCA Vantage® Analyzer helps you monitor glycemic control and detect early kidney disease in environments ranging from the physician’s office to remote, point-of-care coordinated sites in hospitals and multisite practices. Meet lab-quality testing standards with an analyzer that speeds and simplifies diabetes tests and delivers accurate,1 clinically relevant results shown to improve decision-making,2,3 patient compliance, and outcomes.4

Related Products, Services & Resources

References
1. Lenters-Westra E, Slingerland RJ. Clin Chem 2010;56(1):44.
2. Thaler LM, et al. Diabetes Care 1999;22:1415-21.
3. Miller CD, et al. Diabetes Care 2003;26:1158-63.
4. Cagliero E, et al. Diabetes Care 1999;22:1785-9.
5. GHX Market Intelligence, market data report. 4Q 2012 Report.
*. CE Mark Reference 10698776 Rev. A, 2012-08.